"A widely prescribed antipsychotic, aripiprazole, is being linked to persistent hiccups, with emerging evidence suggesting that paradoxically, lower doses may be the culprit. This unusual side effect, while rare, highlights the complex pharmacology of dopamine modulation and the importance of considering medication as a cause for persistent hiccups in psychiatric patients."
Persistent hiccups, often dismissed as a minor annoyance, can escalate into a significant health concern, profoundly impacting a patient’s quality of life. For individuals undergoing psychiatric treatment, these intractable spasms can disrupt essential functions like sleep, eating, and speech, potentially necessitating a change in vital medication. Aripiprazole, a cornerstone in the treatment of various psychiatric conditions in the United States, has been increasingly associated with this peculiar side effect. Intriguingly, the prevailing theory suggests that the problem may not stem from an excessive dose, but rather from a dose that is too low, a counterintuitive finding that warrants a closer examination of the drug’s unique mechanism of action.
A comprehensive review published in Frontiers in Pharmacology in 2024 has begun to coalesce scattered reports, painting a clearer picture of this emerging pattern. This review, alongside a recent case study of a 32-year-old man diagnosed with somatic symptom disorder, has brought the total number of documented aripiprazole-induced hiccups to 29 published case reports. These reports offer valuable insights into the clinical presentation, potential mechanisms, and management strategies for this unusual adverse event.
The Nuances of Dopamine Partial Agonism
Aripiprazole distinguishes itself from many other antipsychotics through its unique pharmacological profile. Unlike traditional agents that primarily block dopamine D2 receptors, aripiprazole functions as a partial agonist. This means it exhibits a dual action: it dampens dopamine signaling in areas of the brain where dopamine levels are high and stimulates signaling in regions where dopamine is deficient. This delicate balance is crucial for its therapeutic efficacy but also contributes to its complex side effect profile.
The prevailing hypothesis for aripiprazole-induced hiccups centers on this dose-dependent partial agonism. A case series published in Case Reports in Psychiatry, detailing three hospitalized patients, proposed that at doses below 7.5 mg daily, aripiprazole might actually act as a dopamine agonist. In this scenario, it could stimulate D2 and D3 receptors located within the brainstem’s hiccup center, thereby triggering the involuntary diaphragmatic contractions characteristic of hiccups. The patients in this series all experienced relief with low doses of gabapentin, a medication often used to manage nerve-related pain and seizures. The authors suggested that gabapentin’s efficacy might stem from its ability to dampen nerve impulse transmission and modulate diaphragmatic activity.
While the pooled data from the Frontiers in Pharmacology review aligns with this theory, it does not definitively confirm it. The reported doses in the analyzed cases ranged from 2.5 mg to 30 mg daily, with approximately half of the cases occurring at the lower end of this spectrum, between 2.5 mg and 10 mg. This distribution lends credence to the idea that lower, potentially agonistic doses, might be more implicated in hiccup induction.
The hiccup reflex itself is a complex physiological event involving the coordinated contraction of the diaphragm and intercostal muscles, followed by the rapid closure of the glottis. The central control of this reflex is understood to involve multiple neurotransmitter systems, including dopamine, serotonin, and GABA. However, the precise neurobiological pathways remain incompletely elucidated. The paradoxical nature of some antipsychotics being reported to both cause and alleviate hiccups underscores the intricate and not yet fully understood relationship between these medications and the hiccup reflex.
Insights from Pooled Case Reports
The collected case reports offer valuable clinical data, particularly regarding the timing of the side effect’s onset and resolution. This information is crucial for clinicians seeking to differentiate drug-induced hiccups from other potential causes. The findings revealed a strong male predominance, with 86.7% of reported cases occurring in men. The age distribution skewed towards adolescents and middle-aged adults.
A particularly striking observation was the rapid onset of hiccups. In 90.9% of the cases, symptoms emerged within one to two days of initiating aripiprazole or adjusting its dosage. This swift onset is a significant clinical clue. Correspondingly, resolution was also rapid, with hiccups typically subsiding within one to four days after discontinuing the medication. Discontinuation emerged as the most effective management strategy, employed in 51.7% of the reported cases. The co-administration of benzodiazepines was also identified as a notable risk factor, suggesting a potential synergistic effect that may increase the likelihood of developing hiccups.
The route of administration also appears to play a role. A report in Psychiatry and Clinical Neurosciences described a patient who experienced hiccups following two separate long-acting injectable administrations of aripiprazole. In both instances, the hiccups began on the third day post-injection and resolved with simethicone and baclofen, respectively. The patient subsequently declined further injections, highlighting the distress caused by the side effect.
Management strategies reported across the literature are diverse and often empirical, reflecting the lack of established protocols for this rare complication. These strategies include discontinuing aripiprazole, reducing the dosage, switching to an alternative antipsychotic, or employing symptomatic treatments such as gabapentin, chlorpromazine, metoclopramide, or baclofen. An earlier review in Psychiatria Danubina echoed similar conclusions regarding the rarity and the need for further characterization of this association.
A Widely Used Medication with a Long Tail of Effects
Understanding the context of aripiprazole’s widespread use is essential when assessing the significance of any associated side effect. Aripiprazole is a key therapeutic agent for schizophrenia, bipolar I disorder, as an adjunctive treatment for major depressive disorder, and for managing irritability associated with autism and Tourette’s disorder. Its general tolerability and comparatively favorable metabolic profile, especially when contrasted with older antipsychotics, contribute significantly to its broad prescription rates.
Medications administered to millions of individuals invariably accumulate a "long tail" of uncommon adverse effects. Hiccups fall squarely into this category. The hiccup reflex is a complex phenomenon that can be triggered by a wide array of underlying conditions, ranging from lesions in the brainstem and gastroesophageal reflux disease to metabolic disturbances and infections. This broad differential diagnosis is precisely why, in a hospitalized psychiatric patient, a new onset of hiccups is often initially investigated as a gastrointestinal issue before the medication list is thoroughly reviewed. As one case report in a pharmacy practice journal noted, the diagnostic workup for unexplained hiccups can become extensive before the possibility of a drug-induced etiology is considered.
The timing of symptom onset serves as a critical discriminating clue for clinicians. A hiccup that begins within a day or two of initiating aripiprazole or a dose adjustment, in the absence of new gastrointestinal symptoms and with a normal chest radiograph, is more likely to be medication-related than a hiccup that emerges months into stable treatment.
The Limitations of Case Reports
It is imperative to acknowledge the inherent limitations of case report literature. The documentation of 29 published cases worldwide does not translate to an incidence rate. Instead, it represents a collection of instances that clinicians deemed unusual enough to warrant reporting. This means that such reports tend to overrepresent dramatic or persistent presentations and provide no insight into the vast number of individuals who take aripiprazole without ever experiencing hiccups. The observed male predominance in reports might reflect prescribing patterns or reporting biases rather than a genuine difference in risk between sexes.
Furthermore, hiccups are not among the commonly recognized adverse effects of aripiprazole. The more established side effects typically include akathisia (restlessness), insomnia, and nausea. For individuals currently taking aripiprazole, it is crucial to understand that the occurrence of hiccups is a rare event. Abruptly discontinuing an antipsychotic medication can carry its own significant risks, including the potential for symptom relapse, and should only be done under strict medical supervision.
The most valuable takeaway from this body of evidence is primarily aimed at healthcare professionals. Clinicians should be aware that hiccups commencing within a day or two of initiating aripiprazole or altering its dosage warrant consideration as a potential drug effect, rather than being immediately attributed to a gastrointestinal complaint.
Individuals experiencing hiccups that persist for longer than 48 hours, regardless of whether they are taking medication, should consult a healthcare provider. Persistent hiccups can signal an underlying medical condition or, as in this context, a medication-related side effect. It is essential that no one adjusts or discontinues a prescribed antipsychotic without professional medical guidance.
Key Questions Answered
What is aripiprazole prescribed for?
Aripiprazole is indicated for the treatment of schizophrenia, bipolar I disorder, as an adjunctive therapy for major depressive disorder, and to manage irritability associated with autism spectrum disorder and Tourette’s disorder.
How common are hiccups as a side effect?
Hiccups are considered a rare side effect of aripiprazole. The existing published literature comprises approximately 29 case reports, which is insufficient to establish a reliable incidence rate.
Why would a low dose cause them?
The prevailing theory suggests that aripiprazole’s action as a dopamine partial agonist may be responsible. At doses typically below 7.5 mg daily, it might act as a dopamine agonist at D2 and D3 receptors located near the brainstem hiccup center, potentially triggering the reflex. However, this mechanism remains to be definitively proven.
How quickly do they start?
In the pooled case reports, a significant majority (90.9%) of patients developed hiccups within one to two days of starting the drug. The symptoms typically resolved within one to four days after discontinuing aripiprazole.
Is there a treatment for the hiccups themselves?
Management strategies reported in the literature include discontinuing the medication, reducing the dosage, switching to a different antipsychotic agent, or using symptomatic treatments such as gabapentin, chlorpromazine, metoclopramide, or baclofen.
When should someone seek help for hiccups?
Hiccups that persist for more than 48 hours warrant medical evaluation. This is because prolonged hiccups can indicate an underlying medical condition or a potential drug-induced side effect.
